Leverage our omni-channel approach to grow your brand across Asia Pacific.
We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.
Discover more about Menarini Group
For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.
Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.
Sharing your partnering idea
Leverage our omni-channel approach to grow your brand across Asia Pacific.
Global Responsibility
FOLLOW US
Global Press Releases
FOLLOW US
MARKETS
The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.
As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.
Our APAC Headquarters
A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD
30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787
Men's Health
Menarini Group entered the Andrology Therapeutic space in the early 2010s. Our acquisition of the rights for the first European-approved oral treatment for Premature Ejaculation (PE) marked the start of our commitment to ease the burden of those suffering from one of the most common male sexual dysfunctions. In 2016, we extended our coverage to include Erectile Dysfunction (ED) treatment, thus offering both physicians and patients a full therapeutic armamentarium in Andrology.
Building on this, Menarini Asia-Pacific acquired Cialis in China in 2020 and Priligy to complement our existing portfolio and deliver total Men’s Health solutions to the region.
